Back

The semaglutide paradox in non-overweight diabetes: a benefit without explanation

European Heart Journal - Quality of Care and Clinical Outcomes

11 August 2025
Organised by: Logo
Read full article
ESC Journals

Contributors

Ahmed B Shamsulddin
Ahmed B Shamsulddin

Author

Al-Yarmouk Teaching Hospital Baghdad , Iraq

You may be interested in
thumbnail
Congress Session
Diabetes, obesity, and heart failure
19 May 2025
thumbnail
Congress Presentation
Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis
31 August 2024
thumbnail
Congress Presentation
Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial
27 August 2021
thumbnail
Congress Presentation
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
7 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources